Cencora, Inc. (NYSE:COR) Shares Sold by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB lessened its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 75.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 621 shares of the company's stock after selling 1,894 shares during the period. Wilmington Savings Fund Society FSB's holdings in Cencora were worth $140,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in COR. Exchange Traded Concepts LLC raised its holdings in shares of Cencora by 41.6% during the third quarter. Exchange Traded Concepts LLC now owns 5,334 shares of the company's stock worth $1,201,000 after purchasing an additional 1,568 shares during the last quarter. CX Institutional increased its holdings in Cencora by 8.0% in the third quarter. CX Institutional now owns 8,868 shares of the company's stock valued at $1,996,000 after buying an additional 654 shares in the last quarter. NBC Securities Inc. increased its holdings in Cencora by 3.9% in the third quarter. NBC Securities Inc. now owns 5,680 shares of the company's stock valued at $1,278,000 after buying an additional 211 shares in the last quarter. Swedbank AB increased its holdings in Cencora by 2.3% in the third quarter. Swedbank AB now owns 1,394,449 shares of the company's stock valued at $313,863,000 after buying an additional 31,104 shares in the last quarter. Finally, Regatta Capital Group LLC increased its holdings in Cencora by 0.7% in the third quarter. Regatta Capital Group LLC now owns 8,576 shares of the company's stock valued at $1,930,000 after buying an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Price Performance

COR traded down $1.50 on Friday, reaching $243.03. 1,277,896 shares of the company's stock were exchanged, compared to its average volume of 1,327,143. The stock has a market cap of $46.97 billion, a PE ratio of 34.57, a P/E/G ratio of 1.49 and a beta of 0.49. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $262.26. The stock's fifty day moving average price is $238.70 and its 200-day moving average price is $237.42. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Sell-side analysts expect that Cencora, Inc. will post 15.36 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. Cencora's dividend payout ratio (DPR) is 31.29%.

Insider Activity

In other news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 73,187 shares of company stock valued at $17,790,912 in the last 90 days. Company insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on COR. Mizuho began coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective for the company. Wells Fargo & Company lifted their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a report on Wednesday, January 29th. UBS Group lifted their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Robert W. Baird lifted their target price on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Finally, Barclays lifted their target price on shares of Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Cencora has an average rating of "Moderate Buy" and a consensus target price of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.